Eurofins Biomnis code

ENDO

Specialty

preventive biology

Clinical significance

Endometriosis affects nearly 10% of women. It evolves on an inflammatory terrain. The patient's pain and subfertility are correlated with the extent of inflammation. Thus, anti-inflammatory treatments can relieve the symptoms, but will in no way solve the origin of the patient's inflammation. Endometriotic cells grow under the influence of estrogen, while progesterone slows down their development. Thus, any imbalance in the estroprogene will promote the development of the disease. The contraceptive pill or artificial menopause are often offered as a solution. Far from being functional, these therapeutic proposals cause many side effects and do not solve the deep problems at the origin of endometriosis. The MyEndoCheck panel explores the different biological abnormalities potentially accompanying endometriosis or, more broadly, a picture of painful periods and/or POS

Preanalytics

• 4 x 1 ml serum (without separating gel): refrigerated ; 3ml EDTA whole blood: refrigerated ; 2 x 1 ml serum (without gel separator): frozen; 1 ml citrated plasma (without separating gel): frozen; 1 ml fluorinated plasma (without separating gel): frozen; 2 x 1 ml of 24H urine (T28): refrigerated;

• A tube specifically for this analysis : No

Further information

Do not use tubes with phase separator
Fasting sample
The sample must be taken on day 7 post-ovulation.
This is a panel of analyses, which must be sent in full to Eurofins Biomnis, without being separated
Attach the specific health questionnaire to the back of the application form.
It is essential to identify the nature of the sample on each tube sent.
Do not combine the Juvenalis report and the Eurofins Biomnis report in the same file.

Documents to download

• Protocole(JU-P47-INTGB)

Methodology

Turnaround time

3 weeks

Caption